{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T17:17:26Z","timestamp":1781111846369,"version":"3.54.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,1,23]],"date-time":"2023-01-23T00:00:00Z","timestamp":1674432000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,23]],"date-time":"2023-01-23T00:00:00Z","timestamp":1674432000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>We demonstrated the non-inferiority of a dexamethasone (DEX)-sparing (single-dose) regimen with NEPA, a netupitant\/palonosetron fixed combination, for preventing chemotherapy-induced nausea and vomiting (CINV) caused by cisplatin. This pre-planned exploratory analysis assessed the effect of the DEX-sparing regimen on a patient\u2019s food intake. Chemotherapy-na\u00efve patients undergoing cisplatin (\u2265\u200970\u00a0mg\/m<jats:sup>2<\/jats:sup>) were given NEPA and DEX (12\u00a0mg) on day 1 and randomized to receive either no further DEX (DEX1), or oral DEX (4\u00a0mg BID) on days 2\u20134 (DEX4). Patient-reported endpoint maintenance of usual daily food intake was assessed during the 5-days post-chemotherapy. The relationship between usual daily food intake and CINV control, pre-chemotherapy self-rated food intake and BMI-adjusted weight loss (WL) were evaluated. One-hundred fifty-two patients (76\/group) were assessable. The proportion of patients reporting maintenance of usual daily food intake was similar in both groups: 69.7% (95% CI, 58.6\u201378.9) for DEX1 vs. 72.4% (95% CI, 61.4\u201381.2) for DEX4. Only CINV control was significantly associated with maintenance of usual daily food intake (<jats:italic>P<\/jats:italic>\u2009\u2264\u20090.001) during the overall phase. The DEX-sparing regimen does not adversely affect patient-reported daily food intake post-chemotherapy. The current analysis adds further insights into antiemetic efficacy of DEX sparing beyond day 1 in the challenging setting of cisplatin.<\/jats:p><jats:p><jats:italic>Trial registration<\/jats:italic>: The parent study was registered on ClinicalTrials.gov (NCT04201769).<\/jats:p>","DOI":"10.1038\/s41598-023-28464-9","type":"journal-article","created":{"date-parts":[[2023,1,23]],"date-time":"2023-01-23T11:03:09Z","timestamp":1674471789000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Exploratory analysis of the effect of a dexamethasone-sparing regimen for prophylaxis of cisplatin-induced emesis on food intake (LUNG-NEPA study)"],"prefix":"10.1038","volume":"13","clinical-trial-number":[{"clinical-trial-number":"nct04201769","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Luigi","family":"Celio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Cortinovis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessio Aligi","family":"Cogoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Cavanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Martelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Carnio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Collov\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Bertolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fausto","family":"Petrelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Cassano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Chiari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Zanelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Pisconti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella","family":"Vittimberga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonietta","family":"Letizia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Misino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Gernone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erminio","family":"Bonizzoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Pilotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabino","family":"De Placido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio","family":"Bria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,23]]},"reference":[{"issue":"suppl 5","key":"28464_CR1","doi-asserted-by":"publisher","first-page":"v119","DOI":"10.1093\/annonc\/mdw270","volume":"27","author":"F Roila","year":"2016","unstructured":"Roila, F. et al. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Ann. Oncol. 27(suppl 5), v119-133 (2016).","journal-title":"Ann. Oncol."},{"key":"28464_CR2","doi-asserted-by":"publisher","first-page":"3240","DOI":"10.1200\/JCO.2017.74.4789","volume":"35","author":"PJ Hesketh","year":"2017","unstructured":"Hesketh, P. J. et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J. Clin. Oncol. 35, 3240\u20133261 (2017).","journal-title":"J. Clin. Oncol."},{"key":"28464_CR3","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s00520-012-1493-9","volume":"21","author":"C Farrell","year":"2013","unstructured":"Farrell, C., Brearley, S. G., Pilling, M. & Molassiotis, A. The impact of chemotherapy-related nausea on patients\u2019 nutritional status, psychological distress and quality of life. Support. Care Cancer 21, 59\u201366 (2013).","journal-title":"Support. Care Cancer"},{"key":"28464_CR4","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/j.jand.2015.10.020","volume":"116","author":"W Marx","year":"2016","unstructured":"Marx, W., Kiss, N., McCarthy, A. L., McKavanagh, D. & Insering, L. Chemotherapy-induced nausea and vomiting: A narrative review to inform dietetics practice. J. Acad. Nutr. Diet 116, 819\u2013827 (2016).","journal-title":"J. Acad. Nutr. Diet"},{"key":"28464_CR5","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1093\/annonc\/mds021","volume":"23","author":"M Aapro","year":"2012","unstructured":"Aapro, M. et al. The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): The Pan European Emesis Registry (PEER). Ann. Oncol. 23, 1986\u20131992 (2012).","journal-title":"Ann. Oncol."},{"key":"28464_CR6","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1200\/JOP.2012.000816","volume":"10","author":"JW Gilmore","year":"2014","unstructured":"Gilmore, J. W. et al. Antiemetic guideline consistency and incidence of chemotherapy-induced nausea and vomiting in US community oncology practice: INSPIRE study. J. Oncol. Pract. 10, 68\u201374 (2014).","journal-title":"J. Oncol. Pract."},{"key":"28464_CR7","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1038\/sj.bjc.6603048","volume":"94","author":"J Vardy","year":"2006","unstructured":"Vardy, J., Chiew, K. S., Galica, J., Pond, G. R. & Tannock, I. F. Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy. Br. J. Cancer 94, 1011\u20131015 (2006).","journal-title":"Br. J. Cancer"},{"key":"28464_CR8","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1634\/theoncologist.2015-0211","volume":"20","author":"HS Han","year":"2015","unstructured":"Han, H. S. et al. A prospective multicenter study evaluating secondary adrenal suppression after antiemetic dexamethasone therapy in cancer patients receiving chemotherapy: A Korean South West Oncology Group study. Oncologist 20, 1432\u20131439 (2015).","journal-title":"Oncologist"},{"key":"28464_CR9","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1634\/theoncologist.2016-0308","volume":"22","author":"M Nakamura","year":"2017","unstructured":"Nakamura, M. et al. A prospective observational study on effect of short-term periodic steroid premedication on bone metabolism in gastrointestinal cancer (ESPRESSO-01). Oncologist 22, 592\u2013600 (2017).","journal-title":"Oncologist"},{"key":"28464_CR10","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.4143\/crt.2015.464","volume":"48","author":"Y Jeong","year":"2016","unstructured":"Jeong, Y. et al. A pilot study evaluating steroid-induced diabetes after antiemetic dexamethasone therapy in chemotherapy-treated cancer patients. Cancer Res. Treat. 48, 1429\u20131437 (2016).","journal-title":"Cancer Res. Treat."},{"key":"28464_CR11","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1093\/annonc\/mdv138","volume":"26","author":"K Jordan","year":"2015","unstructured":"Jordan, K., Jahn, F. & Aapro, M. Recent developments in the prevention of chemotherapy-induced nausea and vomiting (CINV): A comprehensive review. Ann. Oncol. 26, 1081\u20131090 (2015).","journal-title":"Ann. Oncol."},{"key":"28464_CR12","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1093\/annonc\/mdp584","volume":"21","author":"M Aapro","year":"2010","unstructured":"Aapro, M. et al. Double-blind, randomised, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy. Ann. Oncol. 21, 1083\u20131088 (2010).","journal-title":"Ann. Oncol."},{"key":"28464_CR13","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1093\/annonc\/mdu101","volume":"25","author":"M Aapro","year":"2014","unstructured":"Aapro, M. et al. A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy. Ann. Oncol. 25, 1328\u20131333 (2014).","journal-title":"Ann. Oncol."},{"key":"28464_CR14","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1186\/s12885-019-6454-y","volume":"19","author":"L Celio","year":"2019","unstructured":"Celio, L. et al. Impact of dexamethasone-sparing regimens on delayed nausea caused by moderately or highly emetogenic chemotherapy: A meta-analysis of randomised evidence. BMC Cancer 19, 1268 (2019).","journal-title":"BMC Cancer"},{"key":"28464_CR15","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1200\/JCO.2017.74.4375","volume":"36","author":"Y Ito","year":"2018","unstructured":"Ito, Y. et al. Placebo-controlled, double-blind phase III study comparing dexamethasone on day 1 with dexamethasone on days 1 to 3 with combined neurokinin-1 receptor antagonist and palonosetron in high-emetogenic chemotherapy. J. Clin. Oncol. 36, 1000\u20131006 (2018).","journal-title":"J. Clin. Oncol."},{"key":"28464_CR16","doi-asserted-by":"publisher","first-page":"2741","DOI":"10.1200\/JCO.2018.78.8109","volume":"36","author":"L Celio","year":"2018","unstructured":"Celio, L., Bonizzoni, E. & Aapro, M. Is the dexamethasone-sparing strategy ready for cisplatin? Too early for an answer. J. Clin. Oncol. 36, 2741\u20132742 (2018).","journal-title":"J. Clin. Oncol."},{"key":"28464_CR17","doi-asserted-by":"publisher","first-page":"e1854","DOI":"10.1002\/onco.13851","volume":"26","author":"L Celio","year":"2021","unstructured":"Celio, L. et al. Dexamethasone-sparing regimens with oral netupitant and palonosetron for the prevention of emesis caused by high-dose cisplatin: A randomized noninferiority study. Oncologist 26, e1854\u2013e1861 (2021).","journal-title":"Oncologist"},{"key":"28464_CR18","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1081\/CNV-120022376","volume":"21","author":"VT Chang","year":"2003","unstructured":"Chang, V. T. & Ingham, J. Symptom control. Cancer Invest. 21, 564\u2013578 (2003).","journal-title":"Cancer Invest."},{"key":"28464_CR19","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1200\/JCO.2014.56.1894","volume":"33","author":"L Martin","year":"2015","unstructured":"Martin, L. et al. Diagnostic criteria for the classification of cancer-associated weight loss. J. Clin. Oncol. 33, 90\u201399 (2015).","journal-title":"J. Clin. Oncol."},{"key":"28464_CR20","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1038\/sj.ejcn.1601412","volume":"56","author":"J Bauer","year":"2002","unstructured":"Bauer, J., Capra, S. & Ferguson, M. Use of the scored Patient-Generated Subjective Global Assessment (PG-SGA) as a nutrition assessment tool in patients with cancer. Eur. J. Clin. Nutr. 56, 779\u2013785 (2002).","journal-title":"Eur. J. Clin. Nutr."},{"key":"28464_CR21","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.jpainsymman.2010.04.020","volume":"41","author":"SM Watanabe","year":"2011","unstructured":"Watanabe, S. M. et al. A multicentre comparison of two numerical versions of the Edmonton Symptom Assessment System in palliative care patients. J. Pain Symptom Manag. 41, 456\u2013468 (2011).","journal-title":"J. Pain Symptom Manag."},{"key":"28464_CR22","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1007\/s00520-005-0834-3","volume":"14","author":"C Moro","year":"2006","unstructured":"Moro, C. et al. Edmonton symptom assessment scale: Italian version in two palliative care settings. Support. Care Cancer 14, 30\u201337 (2006).","journal-title":"Support. Care Cancer"},{"key":"28464_CR23","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1186\/s12885-020-6707-9","volume":"20","author":"R Caputo","year":"2020","unstructured":"Caputo, R. et al. Netupitant\/palonosetron (NEPA) and dexamethasone for prevention of emesis in breast cancer patients receiving adjuvant anthracycline plus cyclophosphamide: A multi-cycle, phase II study. BMC Cancer 20, 232 (2020).","journal-title":"BMC Cancer"},{"key":"28464_CR24","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1002\/jcsm.12220","volume":"8","author":"OM Vagnildhaug","year":"2017","unstructured":"Vagnildhaug, O. M. et al. The applicability of a weight loss grading system in cancer cachexia: A longitudinal analysis. J. Cachexia Sarcopenia Muscle 8, 789\u2013797 (2017).","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"28464_CR25","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1111\/1759-7714.13830","volume":"12","author":"J Liu","year":"2021","unstructured":"Liu, J. et al. Symptom trajectories during chemotherapy in patients with non-small cell lung cancer (NSCLC) and the function of prolonging low dose dexamethasone in promoting enhanced recovery after chemotherapy. Thorac. Cancer 12, 783\u2013795 (2021).","journal-title":"Thorac. Cancer"},{"key":"28464_CR26","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1200\/JCO.1985.3.10.1379","volume":"10","author":"MG Kris","year":"1985","unstructured":"Kris, M. G. et al. Incidence, course, and severity of delayed nausea and vomiting following the administration of high-dose cisplatin. J. Clin. Oncol. 10, 1379\u20131384 (1985).","journal-title":"J. Clin. Oncol."},{"key":"28464_CR27","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.jpainsymman.2011.11.003","volume":"44","author":"A Molassiotis","year":"2012","unstructured":"Molassiotis, A., Farrell, C., Bourne, K., Brearley, S. G. & Pilling, M. An exploratory study to clarify the cluster of symptoms predictive of chemotherapy-related nausea using random forest modeling. J. Pain Symptom Manag. 44, 692\u2013703 (2012).","journal-title":"J. Pain Symptom Manag."},{"key":"28464_CR28","doi-asserted-by":"publisher","first-page":"e103512","DOI":"10.1371\/journal.pone.0103512","volume":"31","author":"A Boltong","year":"2014","unstructured":"Boltong, A. et al. A prospective cohort study of the effects of adjuvant breast cancer chemotherapy on taste function, food liking, appetite and associated nutritional outcomes. PLoS ONE 31, e103512 (2014).","journal-title":"PLoS ONE"},{"key":"28464_CR29","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1186\/s12885-022-10018-3","volume":"22","author":"L Celio","year":"2022","unstructured":"Celio, L. et al. Evaluating the impact of chemotherapy-induced nausea and vomiting on daily functioning in patients receiving dexamethasone-sparing antiemetic regimens with NEPA (netupitant\/palonosetron) in the cisplatin setting: Results from a randomized phase 3 study. BMC Cancer 22, 915 (2022).","journal-title":"BMC Cancer"},{"key":"28464_CR30","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/S1470-2045(19)30678-3","volume":"21","author":"H Hashimoto","year":"2020","unstructured":"Hashimoto, H. et al. Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 21, 242\u2013249 (2020).","journal-title":"Lancet Oncol."},{"key":"28464_CR31","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1093\/oxfordjournals.annonc.a058928","volume":"5","author":"Italian Group for Antiemetic Research","year":"1994","unstructured":"Italian Group for Antiemetic Research. Cisplatin-induced delayed emesis: Pattern and prognostic factors during three subsequent cycles. Ann. Oncol. 5, 585\u2013589 (1994).","journal-title":"Ann. Oncol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-28464-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-28464-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-28464-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,26]],"date-time":"2023-01-26T13:05:32Z","timestamp":1674738332000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-28464-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,23]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["28464"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-28464-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,23]]},"assertion":[{"value":"10 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Luigi Celio has received consulting fees from Italfarmaco SpA, and Kyowa Kirin; speaker\u2019s fee from Berlin-Chemie AG, and Helsinn. Diego Cortinovis has received speaker\u2019s bureau and scientific advisor fees from Roche, AstraZeneca, BMS, MSD, Boehringer, Amgen, Novartis, and Lilly. Federica Bertolini has received speaker\u2019s fee from MSD, AstraZeneca, and BMS; advisory board fees from MSD, Eli-Lilly, and Sanofi. Rita Chiari has declared speaker's fee - advisory boards from Astrazeneca, Roche, BMS, MSD, Pfizer, and Takeda. Erminio Bonizzoni received consulting fees from Helsinn. Sara Pilotto has received fees for consulting, advisory role and lectures from AstraZeneca, BMS, Boehringer, Eli-Lilly, Merck, Novartis, Roche, Amgen, Takeda. Emilio Bria received speakers\u2019 and travels\u2019 fees from MSD, AstraZeneca, Celgene, Pfizer, Helsinn, Eli-Lilly, BMS, Novartis and Roche, as well as institutional research grants from AstraZeneca and Roche. All remaining authors have declared no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1257"}}